Results 51 to 60 of about 54,679 (264)

Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients

New England Journal of Medicine, 2013
Background In patients with melanoma, ipilimumab (anti-CTLA-4) prolongs overall survival and nivolumab (anti-PD-1) produced durable tumor regressions in a phase 1 trial.
J. Wolchok, H. Kluger, M. Callahan, M. Postow, N. Rizvi, A. Lesokhin, N. Segal, C. Ariyan, R. Gordon, Kathleen Reed, M. Burke, A. Caldwell, S. Kronenberg, B. Agunwamba, Xiaoling Zhang, I. Lowy, H. Inzunza, W. Feely, C. Horak, Q. Hong, A. Korman, J. Wigginton, A. Gupta, M. Sznol   +23 more
semanticscholar   +1 more source

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

Journal of Clinical Oncology, 2022
PURPOSE In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care.
T. André, D. Tougeron, G. Piessen, C. de la Fouchardière, C. Louvet, A. Adenis, M. Jary, C. Tournigand, T. Aparicio, J. Desramé, A. Lièvre, M. Garcia-Larnicol, T. Pudlarz, R. Cohen, Salomé Memmi, D. Vernerey, J. Henriques, J. Lefèvre, M. Svrcek   +18 more
semanticscholar   +1 more source

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

BMC Cancer, 2019
Background Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases.
Mark T. J. van Bussel, Jos H. Beijnen, Dieta Brandsma   +2 more
doaj   +1 more source

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

OncoImmunology, 2018
Introduction: Checkpoint inhibitors, including the CTLA-4 blocking antibody ipilimumab, have become the new standard therapy for many metastatic cancers.
Anders H. Kverneland, Christian Enevold, Marco Donia, Lars Bastholt, Inge Marie Svane, Claus H. Nielsen   +5 more
doaj   +1 more source

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

Journal of Translational Medicine, 2012
Background Ipilimumab and vemurafenib have both been shown to improve survival in phase III trials of patients with metastatic melanoma. Although vemurafenib is associated with a rapid onset of activity, responses are often of limited duration ...
Ascierto Paolo A, Simeone Ester, Giannarelli Diana, Grimaldi Antonio M, Romano Anna, Mozzillo Nicola   +5 more
doaj   +1 more source

Ipilimumab cystic hypophysitis mimicking metastatic melanoma

Radiology Case Reports, 2018
Ipilimumab is an immunotherapeutic agent used in the treatment of metastatic melanoma, and is known to cause hypophysitis in some patients. Magnetic resonance imaging of ipilimumab-induced hypophysitis typically shows diffuse enlargement of the pituitary
John Wallace, BS, Martin Krupa, MD, James Brennan, MD, Frank Mihlon, MD   +3 more
doaj   +1 more source

18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma

Cancer Imaging, 2020
Background Immune checkpoint blockade such as ipilimumab and anti-PD1 monoclonal antibodies have significantly improved survival in advanced melanoma.
Annie Wong, Jason Callahan, Marleen Keyaerts, Bart Neyns, Johanna Mangana, Susanne Aberle, Alan Herschtal, Sonia Fullerton, Donna Milne, Amir Iravani, Grant A. McArthur, Rodney J. Hicks   +11 more
doaj   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab [PDF]

Journal of Immunotherapy and Precision Oncology, 2018
Ipilimumab and nivolumab are human monoclonal antibodies used in cancer therapy. Ipilimumab targets cytotoxic T-lymphocyte-associated antigen and nivolumab acts against programmed death receptor-1. Both drugs have extensive side effect profiles with high
Shelby L Kubicki, Macartney E Welborn, Anisha B Patel   +2 more
doaj   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.

The Lancet
BACKGROUND Patients with unresectable hepatocellular carcinoma have a poor prognosis, and treatments with long-term benefits are needed. We report results from the preplanned interim analysis of the CheckMate 9DW trial assessing nivolumab plus ipilimumab
Thomas Cheung Yau, P. Galle, T. Decaens, B. Sangro, Shukui Qin, L. D. da Fonseca, H. Karachiwala, J. Blanc, Joong-Won Park, E. Gane, M. Pinter, A. M. Peña, M. Ikeda, David Tai, A. Santoro, G. Pizarro, Chang-Fang Chiu, M. Schenker, A.R. He, H. Chon, J. Wójcik-Tomaszewska, G. Verset, Q. Wang, Caitlyn Stromko, J. Neely, Prianka Singh, M. J. Jimenez Exposito, Masatoshi Kudo   +27 more
semanticscholar   +1 more source